FDA's Post-Market NME Safety Reviews "Useful," But May Not Continue
This article was originally published in The Pink Sheet Daily
Executive Summary
Evaluations lead to labeling changes but were resource-intensive, according to agency's final report on a pilot program involving five NMEs.
You may also be interested in...
NME Safety Reviews Expected For Three More Drugs, With FDA Pilot Program Expansion
Agency's decision means that analysis of Doribax, Isentress and Bystolic will be forthcoming.
NME Safety Reviews Expected For Three More Drugs, With FDA Pilot Program Expansion
Agency's decision means that analysis of Doribax, Isentress and Bystolic will be forthcoming.
FDA Safety Pilot Prompts SNRI Relabeling; “Too Soon To Tell” Patient Impact
FDA's pilot program to conduct post-market safety reviews of new molecular entities has catalyzed labeling changes for Lilly's Cymbalta, but its impact on patient safety remains uncertain